29 results about "Complement system" patented technology

The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.

In one aspect, the invention provides compositions and methods for preventing, reducing, and / or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and / or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and / or antithrombosis and / or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

The present invention provides synthetic peptides, compositions containing synthetic peptides, and methods for modifying the complement system. [Solution] The present invention relates to the modification of a 15-amino acid synthetic peptide from polar assortant (PA) peptides, which are scrambled peptides derived from human astrovirus protein. In some embodiments, the present invention relates to peptides that are modified PAs, which are stapled and / or have D-enantiomer substitutions of certain amino acids, and which include sarcosine substitutions at certain amino acid positions. The present invention further provides a method for selecting at least one synthetic peptide to treat various conditions.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

The invention relates to the technical field of aquatic animal immune regulation and control, in particular to rHoLL-like stepped lectin-like recombinant protein as well as a preparation method and application thereof. The recombinant protein has pathogen-related molecular pattern recognition and combination capabilities, can promote aggregation of pathogens in a body fluid environment, and activates an aquatic animal complement system, so that the non-specific immune defense capability is enhanced. The preparation method comprises the following steps: amplifying a HoLL-like mature peptide coding sequence, constructing a recombinant expression vector, and converting the recombinant expression vector into an escherichia coli expression host for induced expression to obtain rHoLL-like lectin-like recombinant protein existing in an inclusion body form; and carrying out affinity chromatography purification on the inclusion body protein, and carrying out renaturation treatment in a manner of gradient reduction of denaturant concentration to obtain the rHoLL-like stepped lectin-like recombinant protein. The rHoLL-like stepped lectin-like recombinant protein has good biological safety, and can be applied to aquaculture as an aquatic animal immunopotentiator or a related biological product.

The invention discloses application of a complement system inhibitor in preparation of a medicine for treating myeloma nephropathy, and belongs to the technical field of pharmaceutical preparations. According to the application disclosed by the invention, the complement activation inhibitor medicines with different action mechanisms are used for intervening the activation of a complement system, so that the deposition of light-chain proteins at the kidney part can be effectively reduced in a myeloma animal model, and the myeloma nephropathy is improved from the source. The invention provides a new idea for the treatment of myeloma nephropathy, and has a good clinical application prospect.

The invention discloses a detection method and a kit for calculating the ratio of serum (plasma) complements C3, C4 and C5 and urine complements C3, C4 and C5 to urine creatinine, which are innovatively developed on a full-automatic analyzer with a touch screen. The method realizes full-automatic detection of an instrument, is simple, convenient and rapid to operate, has stable and reliable performance of the kit, is a good helper for targeted prevention and treatment of complement-related diseases and clinical accompanying diagnosis and treatment, and opens up a new direction for clinical application of multi-item detection of an in-vitro diagnostic technology complement system.

Provided is a use of a recombinant fusion protein in the preparation of a drug for treating an autoimmune disease that can benefit from the reduction or elimination of CD20+B cells (for example, CD20+ B cell depletion therapy). The recombinant fusion protein comprises i) a CD47-binding peptide, and ii) an anti-CD20 antibody or an antigen-binding portion thereof, wherein the CD47-binding peptide comprises a first extracellular Ig-like domain (SIRPαD1) of signal regulatory protein α (SIRPα), and the anti-CD20 antibody or the antigen-binding portion thereof comprises a heavy chain variable region, a heavy chain constant region, a light chain variable region, and a light chain constant region. The heavy chain variable region comprises VH-CDR1, VH-CDR2, and VH-CDR3, and the light chain variable region comprises VL-CDR1, VL-CDR2, and VL-CDR3, wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 respectively comprise amino acid sequences as shown in GYTFTSYN (SEQ ID NO: 1), IYPGNGDT (SEQ ID NO: 2), ARSTYYGGDWYFNV (SEQ ID NO: 3), SSVSY (SEQ ID NO: 4), ATS, and QQWTSNPPT (SEQ ID NO: 5). The heavy chain constant region has the binding capacity for an FcR or a complement system protein. The CD47-binding peptide is linked to the N-terminus of the heavy chain variable region or light chain variable region of the anti-CD20 antibody or the antigen-binding portion thereof.

The inventions relates to Immunoglobulin A (IgA) or a pharmaceutical composition comprising IgA for use in the treatment of an infectious disease of or in an immune privileged organ, such as the eye, fetus, placenta, central nervous system (CNS) and / or testicles caused by a bacterial, fungal, viral or parasitic infection, in particular caused by bacteria of the human microbiome. IgA-coated pathogens can be addressed by FCAR+ and / or CD11c+ innate immune cells, for example by phagocytosis, or by activation of the complement system. The use of IgA or a pharmaceutical composition comprising IgA in immune privileged sites is advantageous because in contrast to IgG, IgA-coated pathogens do not trigger activation of C1q, a protein used for the controlled pruning of synapses. This prevents neuronal damage in said immune privileged organ(s), while at the same time allowing an antibody-mediated immune response in said organs.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

The present invention relates to a method for stabilizing a fast decay component C3bBb complex of a bypass pathway of a complement system as well as a stabilized C3bBb complex and its use.

Compounds, compositions, and methods are provided for treating kidney diseases characterized by complement system dysregulation and / or C3d deposition in the kidneys in patients of need.

The invention discloses a biomarker for coronary heart disease diagnosis and / or severity evaluation and application thereof, and relates to the technical field of biomedical detection and in-vitro diagnosis. The biomarker is at least one of a complement C1r and a complement C8, and the invention further provides application of a detection reagent of the biomarker in preparation of products for coronary heart disease diagnosis and / or coronary heart disease severity evaluation, coronary heart disease early screening and coronary heart disease prognosis evaluation. The invention also provides a kit for diagnosing the coronary heart disease and / or evaluating the severity of the coronary heart disease. The complement C1r and the complement C8 can be used as biomarkers for diagnosing the coronary heart disease and evaluating the severity of the coronary heart disease, and the research blank of the complement system in the field of evaluation of the severity of the coronary heart disease is filled. The detection method is based on a blood sample, invasive operation is not needed, the patient risk and the detection cost are reduced, and the method is suitable for clinical large-scale screening and long-term dynamic monitoring.

The present invention relates to benzopyrazole compounds and analogs thereof. Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of Formula (I), and methods relating to the use of the compounds and compositions to treat and prevent diseases and conditions characterized by aberrant complement system activity.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

The invention relates to a method for rapidly preparing exosomes by using human peripheral blood. In one aspect, the method for preparing plasma exosomes from peripheral blood comprises the following steps: (1) rapidly separating plasma components of the peripheral blood obtained from healthy donors or non-specific disease patients by using a differential centrifugation method; (2) performing thermal inactivation to remove a complement system in the plasma; (3) gradually removing impurities (such as substances including protein, polypeptide, fibrinogen and the like) in the plasma by a differential centrifugation method; and (4) precipitating the exosome component in the plasma by a PEG6000 method, and washing the precipitate to obtain the exosome. The invention further relates to the plasma exosome prepared from peripheral blood, the maximum value of particle size distribution of the plasma exosome is within the range of 80-200 nm, the positive rate of CD9-PE is larger than 70%, and the positive rate of CD81-PE is larger than 80%. The method disclosed by the invention can be used for rapidly and efficiently obtaining the exosome from the human peripheral blood.

The invention relates to an exosome and a method for preparing the exosome by using umbilical cord blood. On one hand, the maximum value of particle size distribution of the plasma exosome prepared from the umbilical cord blood provided by the invention is in a range of 80-200nm, the positive rate of CD9-PE is greater than 75%, and the positive rate of CD81-PE is greater than 80%. The exosome is prepared according to the method comprising the following steps: (1) quickly separating plasma components of fresh umbilical cord blood obtained from parturition of a puerpera by using a differential centrifugation method; (2) performing thermal inactivation to remove a complement system in the plasma; (3) gradually removing impurities in the plasma by a differential centrifugation method; and (4) precipitating the exosome component in the plasma by a PEG6000 method, and washing the precipitate to obtain the exosome. The invention also relates to a method for preparing the exosome from the plasma by quickly separating the umbilical cord blood by a differential centrifugation method and then by a PEG precipitation method. The method disclosed by the invention can be used for rapidly and efficiently preparing the exosome.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

The present invention relates to a method for stabilizing the C3bBb complex, a rapidly decaying component of the alternative pathway of the complement system, and stabilized C3bBb complexes and uses thereof.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

The invention provides a single-domain antibody combined with human C3b, and a fusion protein, a nucleic acid, a recombinant vector, a host cell and a composition based on the single-domain antibody. Also provided are methods of use and uses thereof, e.g., for treating or preventing diseases or conditions associated with abnormal activation of the complement system.

The invention belongs to the field of traditional Chinese medicine preparation, and relates to application of biflavone compounds isochamaejasmine and genkwanol A in preparation of anti-complement drugs. According to the present invention, the biflavone compounds such as the isochamaejasme and the genkwanol A are extracted from the ethyl acetate extraction part of the ethanol extract of the dried root of Stellera tianshanica plant Stellera tianshanica Pod. The in-vitro anti-complement activity evaluation experiment results prove that the biflavone compounds such as the isochamaejasme and the genkwanol A have strong inhibition effects on the classical pathway and the alternative pathway of the complement system, wherein the stellera tianshanica and the genkwanol A are extracted from the ethyl acetate extraction part of the ethanol extract of the dried root of Stellera tianshanica Pod. The biflavone compound isochamaejasmine and genkwanol A can be further used for preparing medicines for treating complement related diseases, and the complement related diseases comprise systemic lupus erythematosus, rheumatoid arthritis or acute respiratory distress syndrome.

We provide peptide-based inhibitors for different pathways in the complement system. [Solution] The present invention provides synthetic peptides. The present invention relates to the modification of a 15-amino acid synthetic peptide from polar assortant (PA) peptides, which are scrambled peptides derived from human astrovirus protein. In some embodiments, the present invention relates to peptides that are modified PAs, which are stapled and / or have D-enantiomer substitutions of certain amino acids, and which include sarcosine substitutions at certain amino acid positions. The present invention further provides a method for selecting at least one synthetic peptide to treat various conditions.

A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.